Lawrence D. Kaplan

MD

Director, Lymphoma Program
Hematologist-oncologist

About me

Dr. Lawrence D. Kaplan, a hematologist-oncologist, directs UCSF's lymphoma program. He is an international leader in the treatment of lymphoma and HIV-associated lymphoma.

In his research, Kaplan is particularly interested in developing new treatments for lymphoma and the HIV-related form of this cancer.

Kaplan earned his medical degree at the David Geffen School of Medicine at UCLA. He completed a residency in medicine at Boston Medical Center and completed a fellowship in hematology and oncology at UCSF. He joined UCSF in 1985.

Kaplan's professional activities include serving on the Lymphoma Working Group of the AIDS Malignancy Consortium, a clinical trials group supported by the National Cancer Institute (NCI). He formerly chaired the group's steering committee. He also serves on the lymphoma committee of Alliance for Clinical Trials in Oncology, a national research group sponsored by the NCI.

  • Education

    UCLA, 1980

  • Residencies

    Boston Medical Center, Medicine, 1983

  • Fellowships

    UCSF, Hematology and Oncology, 1985

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    French

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

Decorative Caduceus

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving ...

This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an origina...

Recruiting

Decorative Caduceus

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic...

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the reco...

Recruiting

Decorative Caduceus

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorub...

This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients wi...

Recruiting

Share